Table 2 Clinical features of the 111 systemic lupus erythematosus (SLE) patients
Clinical variables | Value |
|---|---|
Duration SLE since diagnosis, years | 9.0 (5.0 to 17.0) (range 0 to 40) |
Systolic blood pressure, mmHg | 127.7 (20.1) |
Diastolic blood pressure, mmHg | 78.7 (12.1) |
A history of lupus nephritis, n (%) | 38 (34.2%) |
SLEDAI | 2.0 (0 to 5.25) (range 0 to 27) |
SLICC index | 1 (0 to 3) (range 0 to 8) |
Complement C3, g/l | 0.93 (0.22) |
Complement C4, g/l | 0.17 (0.12 to 0.23) |
Complement C1q, mg/l | 88.6 (28.1) |
Treatment variables | |
Current use of immune-modulatory treatment, n (%) | 94 (84.7%) |
Glucocorticoids | 67 (60.4%) |
Glucocorticoid dose (mg/day) | 5.0 (3.75 to 10.0) |
Antimalarial | 53 (47.7%) |
Azathioprine | 24 (21.6%) |
Mycophenolatmofetil | 9 (8.1%) |
Cyclosporine A | 7 (6.3%) |
Methotrexate | 10 (9%) |
No disease-modifying anti-rheumatic drugs | 17 (15.3%) |
Ever use of glucocorticoids, n (%) | 99 (89.2%) |
Total duration of glucocorticoid use, months | 54 (14 to 113) |
Total glucocorticoid cumulative dose, g | 11.4 (3.5 to 24.5) |
Average glucocorticoid dose, mg/day | 4.3 (3.4) |
Last year glucocorticoid cumulative dose, g | 1.4 (0 to 2,3) |
Last year glucocorticoid average dose, mg/day | 3.8 (0 to 6.3) |